Cited by 727Atrial Fibrillation Management and OutcomesCardiovascular and Diving-Related ComplicationsAcute Ischemic Stroke Management

Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation

Open access
Reddy, Vivek Y., Möbius-Winkler, Sven, Miller, Marc A., Neuzil, Petr, Schuler, Gerhard, Wiebe, Jens, Sick, Peter, Sievert, Horst·2013·Journal of the American College of Cardiology

Abstract

Objectives The purpose of this study was to assess the safety and efficacy of left atrial appendage (LAA) closure in nonvalvular atrial fibrillation (AF) patients ineligible for warfarin therapy.Background The PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that LAA closure with the Watchman device (Boston Scientific, Natick, Massachusetts) was noninferior to warfarin therapy. However, the PROTECT AF trial only included patients who were candidates for warfarin, and even patients randomly assigned to the LAA closure arm received concomitant warfarin for 6 weeks after Watchman implantation.Methods A multicenter, prospective, nonrandomized study was conducted of LAA closure with the Watchman device in 150 patients with nonvalvular AF and CHADS₂ (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and prior stroke or transient ischemic attack) score ≥1, who were considered ineligible for warfarin. The primary efficacy endpoint was the combined events of ischemic stroke, hemorrhagic stroke, systemic embolism, and cardiovascular/unexplained death.Results The mean CHADS₂ score and CHA₂DS₂-VASc (CHADS₂ score plus 2 points for age ≥75 years and 1 point for vascular disease, age 65 to 74 years, or female sex) score were 2.8 ± 1.2 and 4.4 ± 1.7, respectively. History of hemorrhagic/bleeding tendencies (93%) was the most common reason for warfarin ineligibility. Mean duration of follow-up was 14.4 ± 8.6 months. Serious procedure- or device-related safety events occurred in 8.7% of patients (13 of 150 patients). All-cause stroke or systemic embolism occurred in 4 patients (2.3% per year): ischemic stroke in 3 patients (1.7% per year) and hemorrhagic stroke in 1 patient (0.6% per year). This ischemic stroke rate was less than that expected (7.3% per year) based on the CHADS₂ scores of the patient cohort.Conclusions LAA closure with the Watchman device can be safely performed without a warfarin transition, and is a reasonable alternative to consider for patients at high risk for stroke but with contraindications to systemic oral anticoagulation. (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology [ASAP]; NCT00851578).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2013.03.035

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 31 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [8]8. Lip G.Y., Andreotti F., Fauchier L. et al: Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association. Europace 2011; 13: 723. Crossref PubMed Google Scholar

Cited by

Sorted by citations

Authors
Reddy, V. Y., Möbius-Winkler, S., Miller, M. A., Neuzil, P., Schuler, G., Wiebe, J., Sick, P., & Sievert, H.
Affiliations
  • Icahn School of Medicine at Mount Sinai (US)
  • Leipzig Heart Institute (DE)
  • Cardiovascular Center Frankfurt (DE)
  • Krankenhaus Barmherzige Brüder (DE)
Corresponding author
Reddy, Vivek Y.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2013-06
Volume
61
Issue
25
Pages
2551-2556
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2115996784
Cited by
727
References
31
Citations by year
2026: 25 · 2025: 28 · 2024: 46 · 2023: 51 · 2022: 43 · 2021: 57 · 2020: 48 · 2019: 59 · 2018: 61 · 2017: 72 · 2016: 83 · 2015: 75 · 2014: 59 · 2013: 17 · 2012: 1
FWCI
52.98
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Boston Scientific
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cardiovascular and Diving-Related Complications
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
Keywords
left atrial appendage closure, Watchman device, non-valvular atrial fibrillation, stroke prevention, systemic embolism, CHADS2 score, CHA2DS2-VASc score, bleeding risk, procedural safety, ischemic stroke, hemorrhagic stroke, anticoagulation alternatives
MeSH terms
Contraindications, Clopidogrel, Administration, Oral, Aged, Aged, 80 and over, Anticoagulants, Feasibility Studies, Female, Follow-Up Studies, Humans, Male, Platelet Aggregation Inhibitors, Prospective Studies, Ticlopidine, Treatment Outcome, Atrial Appendage

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review